Optimization of size controlled poly (lactide-co-glycolic acid) nanoparticles using quality by design concept

Abstract

Quality by design (QbD) is a risk management and science-based approach laid down by the ICH as well as other Regulatory agencies to enhance pharmaceutical development throughout a product’s lifecycle. Poly(lactide-co-glycolic acid) (PLGA) is the material of choice for development of depot particulate formulations due to its biodegradable nature and is also considered as the ‘green’ eco-friendly material due its biocompatibility and non-toxic properties. Further, PLGA based formulations are approved by regulatory agencies and currently in clinical practice. The aim of the current investigation involves formulation, optimization and in vitro characterization of size controlled PLGA based nanoparticles by employing modified nanoprecipitation technique. An initial risk-assessment analysis was conducted with different formulation and process variables along with their impact on critical quality attributes of the formulation which were identified as particle size and percentage process yield. The Ishikawa diagram was employed to determine the potential risk factors and subsequently optimized by statistical experimental design concept. Box–Behnken design was utilized to optimize nanoparticles and further characterizing the optimized nanoparticulate formulation in vitro. From the present study, it can be concluded that PLGA based nanoparticles with controlled particle size and process yield can be obtained by inculcating the concept of QbD in the product development.